Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients
Journal of Cardiothoracic and Vascular Anesthesia · 2024
DOI: 10.1053/j.jvca.2023.09.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2024. Verfasst von Julia K Lessing und 4 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Hospital, Department of Pharmacy, Durham, NC. Electronic address: Julia.lessing@duke.edu. Hauptthemen laut MEDLINE: Droxidopa, Midodrine, Hypotension. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the effects of droxidopa or atomoxetine on intravenous (IV) vasoactive agent discontinuation in cardiothoracic intensive care unit (ICU) patients with hypotension refractory to midodrine. DESIGN: Single-center, retrospective cohort study. SETTING: Tertiary- and quaternary-care university teaching hospital. PARTICIPANTS: Included patients who received at least 4 consecutive doses of droxidopa or atomoxetine and remained on concurrent midodrine. Patients were excluded if they received study medication before admission, had clinical deterioration after study medication initiation requiring additional vasoactives/escalation of IV vasoactive dosage for at least 12 hours, had a diagnosis of hepatorenal syndrome, were prisoners, or were pregnant. INTERVENTIONS: Droxidopa, atomoxetine, or both. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was time to discontinuation of IV vasoactive agents after initiation of study medication, analyzed using a Kaplan-Meier estimate with the Wilcoxon method, censoring death within 24 hours of the last dose of study medication. No adjustment for repetitive analyses was made, as the analysis was hypothesis-generating. Of the 72 charts reviewed, 45 patients met inclusion criteria (18 atomoxetine, 17 droxidopa, and 10 both). There were no differences in median time to discontinuation of IV vasoactive agents (21.9 days v 8.0 days v 13.9 days, respectively; p = 0.259) or ICU or hospital length of stay between groups. A higher percentage of patients who survived to hospital discharge received both study medications or droxidopa alone (90% v 76.5%) than atomoxetine alone (44.4%, p = 0.028). CONCLUSIONS: Droxidopa and atomoxetine are oral vasoactive agents with potential mechanisms to facilitate IV vasopressor weaning for patients in the ICU with hypotension refractory to midodrine, but further prospective research is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Hospital, Department of Pharmacy, Durham, NC. Electronic address: Julia.lessing@duke.edu.
- Duke University Hospital, Department of Pharmacy, Durham, NC.
- Duke University Hospital, Departments of Anesthesiology, Critical Care, and Surgery (Cardiothoracic), Duke University School of Medicine, Durham NC.
- Division of Cardiology, Duke University School of Medicine, Durham, NC.
Zitieren
APA
Lessing, J. K., Kram, S. J., Levy, J. H., Grecu, L. M., & Katz, J. N. (2024). Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2023.09.023
Vancouver
Lessing JK, Kram SJ, Levy JH, Grecu LM, Katz JN. Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia. 2024. doi:10.1053/j.jvca.2023.09.023
BibTeX
@article{Lessing2024,
author = {Lessing, Julia K and Kram, Shawn J and Levy, Jerrold H and Grecu, Loreta M and Katz, Jason N},
title = {Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients},
journal = {Journal of Cardiothoracic and Vascular Anesthesia},
year = {2024},
doi = {10.1053/j.jvca.2023.09.023}
}
EUVIMED